FDA 483 - Apitoria Pharma Private Limited - September 27, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Apitoria Pharma Private Limited in Sanga Reddy District, Telangana, India, revealed ten significant deficiencies in their API manufacturing operations. The observations highlight inadequate equipment maintenance and qualification, insufficient manufacturing instructions and personnel training, and failures in quality unit oversight, water system design, and deviation investigations. These issues collectively indicate a broad lack of adherence to cGMP principles, posing a moderate to severe risk to the quality and integrity of drug substances.
ID · c88a9780-f209-45af-8216-dbd21e03a3ee